Data obtained from a new study GALIANT shows Galvus® (vildagliptin), an oral treatment for type 2 diabetes, is better tolerated and as effective as commonly prescribed anti-diabetic oral medicines, called thiazolidinediones (TZDs), when added to metformin. Galvus also eliminates a common side effect of other type 2 diabetes medicines – weight gain, by providing for control of body weight . Other data presented also demonstrated the favorable cardiovascular safety profile of Galvus and confirmed its tolerability in patients with mild-to-moderate renal impairment. A lower overall incidence of adverse cardiovascular events was recorded.